MGMT and glioblastoma: Collectively, to help inform and prioritise candidate strategies for assessment within the rapidly evolving clinical trial landscape, our data suggest that PARPi and ATRi, as well as other DDRi in combination with IR, TMZ and TTFields, are worth investigating within a larger panel of primary, patient-derived GSC models representing a range of molecular and phenotypic contexts to further build on data generated in these studies using G1 and G7 GSCs which both represent MGMT methylated glioblastoma (IDH wildtype).